Search
D-Proline
go.drugbank.com/drugs/DB02853ExperimentalThese amino acids may be of bacterial origin, but there is also evidence that they are endogenously produced through amino acid racemase activity [A19263].
Volixibat
go.drugbank.com/drugs/DB13914InvestigationalVolixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. … According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments
Lumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnThe exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.
Daunorubicin
go.drugbank.com/drugs/DB00694ApprovedInvestigationalA very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Cloxacillin
go.drugbank.com/drugs/DB01147ApprovedInvestigationalVet approvedA semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.
Clidinium
go.drugbank.com/drugs/DB00771ApprovedClidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylc...
Rivoglitazone
go.drugbank.com/drugs/DB09200InvestigationalIt is being developed by Daiichi Sankyo Co.
Fosinoprilat
go.drugbank.com/drugs/DB14207ExperimentalFosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.
AG0302-COVID19
go.drugbank.com/drugs/DB16435InvestigationalSponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].
VAD-044
go.drugbank.com/drugs/DB17697InvestigationalVAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]